Heme/Onc fellow @UTHealthSA | Internal Medicine @JacobiHosp @EinsteinMed | Alum @uoaofficial | 🇬🇷 🇱🇧 | Interested in malignant heme 🩸
San Antonio, TX
Joined December 2022
- Tweets60
- Following276
- Followers170
- Likes293
Shoutout to Dr @KateIdaLathrop for moderating a great discussion on how to make the most of conferences.
Because after the meeting, what matters is what you learned, who you met, and how you put it into practice—especially early in your career.@LSOM_HemOnc @precisca_
Thank you, @precisca_ and Dr @OncDocMJ for another excellent event bringing together thoughtful discussions, and valuable takeaways for fellows. Always great to learn from different viewpoints and leave with practical insights to carry forward. 🙌#HemeOnc
Eleftheria Atalla, MD retweeted
Great day at @ASCO headquarters for the FDA/ASCO Hematology & Oncology Fellows’ Day Workshop. Phenomenal presentations on the drug approval process and how the @FDA is on everyone’s team as they work to balance getting promising new therapies to patients as quickly as possible while ensuring they are safe and effective.
@tobechukwuokobi @tonygazibo @NazliDizman @Adhikari_Nawa @EllieAtalla
#cancer
#oncology
#asco
#fda
Eleftheria Atalla, MD retweeted
UT Health San Antonio/Mays Cancer Center Hematology/Oncology Fellowship 2026-2027!
@HemOncFellows
@KateIdaLathrop
@DrSAHaddad
@theglpman
@DanielaUruetamd
@EllieAtalla
@Krishnahdoshi
@AnumjalilMD
@OscarAndreHino1
@mayscancer
@UTSA
Eleftheria Atalla, MD retweeted
Trastuzumab +/- Pert + ET + Palbo after induction chemo now @US_FDA ✅ based off PATINA. This has been the SoC in 1L HR+ HER2+ mBC since its presentation at #SABCS24
- mPFS 44.3mos vs 29.1mos (HR: 0.74)
- #SABC25: At 3yr, improved CNS progression (or death)
#bcsm #OncTwitter
Eleftheria Atalla, MD retweeted
ASH is proud to honor 11 distinguished hematologists with its most prestigious awards and named lectures, recognizing transformative contributions that have advanced research, patient care, and education in blood diseases.
🔗ow.ly/p3TJ50ZfSjg
#Hematology #ASHAwards
🔥 Hot off the press 📚:
An all-oral regimen for newly diagnosed AML in older and unfit patients shows impressive remission rates (CR 47%, CR/CRi 63% and mOS 15.5 months) and opens the path for frontline AML treatment out of the infusion center 🙌
In a phase 1–2 trial involving patients with acute myeloid leukemia, the use of oral decitabine–cedazuridine with venetoclax induced a complete response in 47% of patients, with expected myelosuppressive effects. Full ASCERTAIN-V trial results: nej.md/4fpoGzl
Try asking AI Companion to break this article down into teaching points for you.
ALT Chart titled "Percentage of Patients Who Received Venetoclax for 28 Days" from "All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia" published in the New England Journal of Medicine. The chart compares percentages across three cycles.
Congrats to @theglpman for such a great talk!👏
Real-world analysis demonstrated a 51% reduction in AML risk among high-risk adults, with even greater reductions observed in patients with prior chemotherapy exposure. No new safety signals identified 🚨
@mayscancer
@LSOM_HemOnc
Paradigms in Practice 2026
Thank you @chadinabhan for putting together another outstanding talk that beautifully wraps up the highlights of ASCO, presented by some of the most brilliant oncologists in the field🙌
@VKaklamani
@BalazsHalmosMD @PGrivasMDPhD
@precisca_
@OncDocMJ – at Chicago, IL
Eleftheria Atalla, MD retweeted
Come check out @npgotera and @theglpman posters in the exhibit hall! Proud cofellow moment #ASCO26
@ASCO
@ASCOTECAG
@LSOM_HemOnc
@HemOncFellows
@oncodaily
@UTHSAResearch
@mayscancer
@OscarAndreHino1
@VKaklamani
@KateIdaLathrop
@SabaShaikhMD
@mazo_md
Clinical trials 101: One of the most informative panel sessions I’ve attended so far! Insightful perspectives and valuable input from some of the brightest clinical investigators in the field!
Thank you @ASCOTECAG for arranging such an amazing session!
#RASolute-302: The most awaited plenary session of #ASCO206, changing the landscape of metastatic pancreatic cancer treatment.
What an incredible time to be an oncologist 🙌
5. RASolute-302: Daraxonrasib (pan-RAS inhibitor) vs. chemo in 2L metastatic pancreatic adenocarcinoma:
- Majority of PDAC harbor RAS mutation (more than 90%)
- mOS (in all comers): 13.2mos vs. 6.7mos (HR: 0.40)
- Gr ≥ 3 AEs: 62% vs. 70%
- New SoC/paradigm shifting!!
6/6
nitter.gq/rachnatshroff/status/2…
Strong Jacobi representation at #ASCO2026 🙌
Always glad to reconnect with former colleagues and see them thriving in their careers 💪
@rahul2u
@KarunNeupaneMD
@jmcchiefs
@AndrewGutwein
First day of my first ASCO in the books! 🙌 Grateful for the opportunity to connect with colleagues, meeting new faces, and learning from so many brilliant minds!
Can't wait for the rest of the meeting🙌
#ASCO26
@DrSAHaddad
@OncologyOdyssey
@lungoncdoc
@OncDocMJ
@VKaklamani
Eleftheria Atalla, MD retweeted
Even though we are at #asco26 we cannot get away from #sabcs @SABCSSanAntonio @mayscancer @LSOM_HemOnc
UT San Antonio in da house 🙌
#ASCO2026
Breast Team Best Team at #ASCO26
@VKaklamani
@KateIdaLathrop
@EllieAtalla
@mazo_md
@mayscancer
@LSOM_HemOnc
Eleftheria Atalla, MD retweeted
The @ASCO @IMG_Oncologists happening now during #ASCO26 as part of the ASCO Community of Practice.
@ASCO is one of most inclusive organizations!
And don’t forget to be an @ASCO member:
memberships.asco.org/members…
#belong
